ROLE OF NK CYTOTOXIC FACTOR NKCF IN NK CYTOTOXICITY
Project Number5R01CA035791-06
Contact PI/Project LeaderBONAVIDA, BENJAMIN
Awardee OrganizationUNIVERSITY OF CALIFORNIA LOS ANGELES
Description
Abstract Text
Previous studies of the natural killer (NK) lytic mechanism have provided
evidence for the stimulus secretion model and led to the postulation that
lytic mediators are transferred from the effector to the target cell.
Subsequent work in our laboratory has demonstrated that soluble natural
killer cytotoxic factors (NKCF) can be detected in the supernatant of
effector cells stimulated with NK targets. These factors are NK specific
and lyse only NK sensitive targets. Further studies have shown that NKCF
conform with known characteristics of the NK CMC reaction and we have
postulated that NKCF plays a role in NK CMC cytotoxicity function. The
following model for NK CMC was then proposed by which, following effector
target cell binding, the target stimulates the effector to release NKCF.
These factors then bind to and lyse the target cells. Preliminary studies
have shown that NKCF are glycoproteins and can be fractionated on HPLC
gel-filtration into cytotoxic fractions of molecular weight 20-30
kilodaltons. Furthermore, we have been able to generate xeno and
monoclonal antibodies that can inhibit NK CMC sctivity and in a few
instances neutralize NKCF activity. In the proposal we plan to: 1)
further characterize and biochemically purify NKCF to homogeneity, 2)
characterize antibodies (poly or monoclonal) specific for NKCF, and examine
their role in NK CMC reactions, and 3) in collaboration with other
investigators, compare NKCF with recently described cytolytic granules or
cytotoxins and lymphotoxins derived from NK and CTL lines. We will use
conventional methods of protein purification and structure analysis.
Conventional and monoclonal antibodies will be generated against NKCF and
will be characterized for their role in blocking NK CMC reactions. The
studies proposed are significant and unique in the field of CMC. They are
also clinically important since they describe naturally derived antitumor
cytolytic molecules that may be relevant in immunotherapy. (LB)
No Sub Projects information available for 5R01CA035791-06
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA035791-06
Patents
No Patents information available for 5R01CA035791-06
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA035791-06
Clinical Studies
No Clinical Studies information available for 5R01CA035791-06
News and More
Related News Releases
No news release information available for 5R01CA035791-06
History
No Historical information available for 5R01CA035791-06
Similar Projects
No Similar Projects information available for 5R01CA035791-06